RxDoctor Payments Data

Blake Morris, MD

Interventional Cardiology · Oklahoma City, OKNPI 1760776975

Payments from drug & device makers

$1,416in general payments, 2019–2025

Across 81 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$306
  • Pfizer$143
  • Edwards Lifesciences$92
  • Boehringer Ingelheim$89
  • Merck$83
  • Amgen$76
  • plus $628 from 15 others

What the payments were for

  • Food & beverage$1,39598%
  • Education$222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,416 in reported general payments places this provider in the 15th percentile of 110 interventional cardiology providers in Oklahoma.

See all interventional cardiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$208,931
Medicare patients
1,122
Services billed
2,725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban572$638,208
EntrestoSacubitril/Valsartan104$145,590
XareltoRivaroxaban154$142,223
FarxigaDapagliflozin Propanediol72$88,739
Repatha SureclickEvolocumab60$59,099
JardianceEmpagliflozin53$53,129
MultaqDronedarone Hcl20$36,124
BrilintaTicagrelor39$30,989
Atorvastatin Calcium876$12,055
Metoprolol Succinate691$11,445
VascepaIcosapent Ethyl13$8,144
Ezetimibe282$7,986
Rosuvastatin Calcium389$7,123
Ranolazine ErRanolazine78$6,763
Valsartan253$5,881

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$143$638,208572 claims
NovartisEntresto$74$145,590104 claims
Johnson & JohnsonXarelto$67$142,223154 claims
AstraZenecaFarxiga, Brilinta$306$119,728111 claims
Boehringer IngelheimJardiance$89$53,12953 claims
Sanofi-aventis U.S. LLCMultaq$28$36,12420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 110 interventional cardiology providers in Oklahoma.

Other interventional cardiology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →